Masaki Yamaguchi

Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.

Journal: International journal of clinical oncology
Published: April 03, 2025

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

Journal: EClinicalMedicine
Published: April 26, 2024

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.

Journal: EClinicalMedicine
Published: April 09, 2024

Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.

Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.

Journal: Global health & medicine
Published: March 02, 2024

Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease.

Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease.

Journal: International journal of hematology
Published: January 24, 2024

Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Journal: International journal of clinical oncology
Published: September 13, 2023

Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.

Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Published: October 01, 2022

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.

Journal: Annals of hematology
Published: September 06, 2022

Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.

Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.

Journal: European journal of haematology
Published: August 16, 2022

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Journal: Blood
Published: December 22, 2021

BCR::ABL1-positive histiocytic sarcoma of the small intestine in a patient with chronic myeloid leukaemia.

BCR::ABL1-positive histiocytic sarcoma of the small intestine in a patient with chronic myeloid leukaemia.

Journal: Histopathology
Published: July 12, 2021

Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.

Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.

Journal: Cancer immunology, immunotherapy : CII
Published: May 20, 2021
Showing 1-12 of 19

Last Updated: 09/26/2026